OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 09:50:03 2024-06-27 am EDT | ||
| 17.92 EUR | -1.65% |
|
| Current month | -7.18% | ||
| 1 month | -6.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 17.92 | -1.65% |
| 24-06-26 | 18.22 | 0.00% |
| 24-06-25 | 18.22 | +1.73% |
| 24-06-24 | 17.91 | -2.87% |
| 24-06-21 | 18.44 | -0.16% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 09:50 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6Y2H |
| ISIN | DE000SU6Y2H1 |
| Date issued | 2024-01-15 |
| Strike | 668.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.83 € |
|---|---|
| Lowest since issue | 16.5 € |
| Spread | 0.06 € |
| Spread % | 0.33% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
